C-6 Substituted Estradiol Modulates LPL and ApoC2 for CNS Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective ways to modulate lipoprotein lipase (LPL) and apolipoprotein C2 (ApoC2) expression and activity for therapeutic treatment of peripheral and central nervous system tissue diseases, including inflammation, type-2 diabetes, cardiovascular disease, and obesity, and there is a need to switch microglia or macrophages from a pro-inflammatory to an anti-inflammatory phenotype.
Innovation Solution
A method involving compounds of structural formula I, which up-regulate LPL and/or ApoC2 expression and activity, administered to subjects in need, to enhance anti-inflammatory microglial or macrophage phenotypes and modulate lipid metabolism, thereby treating various disease states such as type-2 diabetes, cardiovascular disease, and CNS tissue diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If LPL and ApoC2 expression and activity are modulated for therapeutic treatment, then treatment effectiveness for peripheral and CNS tissue diseases is improved, but lack of effective modulation methods prevents achieving this improvement
Solution Approach 1:
The patent applies parameter changes by identifying and modifying specific molecular parameters (LPL and ApoC2 expression levels and enzymatic activity) to achieve therapeutic effects. The invention changes the expression and activity parameters of these lipoprotein metabolism proteins to treat various disease states, thereby resolving the contradiction between treatment effectiveness and availability of modulation methods.
2Object-affected harmful factors
If microglia or macrophages are switched from pro-inflammatory to anti-inflammatory phenotype, then inflammation in peripheral or CNS tissue is reduced, but lack of effective phenotype modulation methods prevents achieving this
Solution Approach 1:
The patent changes the phenotypic parameters of microglia and macrophages by modulating LPL and ApoC2 expression, thereby switching cells from pro-inflammatory to anti-inflammatory phenotype. This parameter change approach enables effective inflammation reduction while providing the previously lacking modulation method.
3Productivity
If LPL and ApoC2 expression and activity are up-regulated to enhance anti-inflammatory phenotype, then lipid metabolism is improved, but lack of effective up-regulation compounds prevents achieving this
Solution Approach 1:
The patent introduces intermediary compounds that mediate the up-regulation of LPL and ApoC2 expression and activity. These intermediary substances serve as the missing link to achieve enhanced lipid metabolism by effectively increasing the expression and activity of key lipoprotein metabolism proteins.
4Adaptability or versatility
If effective modulation methods for LPL and ApoC2 are developed, then treatment of various disease states becomes possible, but current lack of such methods creates a barrier to treatment
Solution Approach 1:
The patent achieves universality by developing modulation methods that can be applied across multiple disease states (peripheral tissue diseases, CNS diseases, metabolic disorders) through the common mechanism of LPL and ApoC2 expression and activity modulation. This multi-functional approach enables treatment of various conditions without requiring disease-specific separate methods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively up-regulates LPL expression and activity, promoting an anti-inflammatory phenotype in microglia or macrophages, reducing inflammation, and improving lipid metabolism, thus treating and preventing conditions like type-2 diabetes, cardiovascular disease, and CNS disorders.
Implementation Method 1
Lipoprotein lipase (LPL) and apolipoprotein C2 (ApoC2) are key enzymes in lipid metabolism and involved in the hydrolysis of triglyceride (TG)-rich lipoproteins
Data Source
AI summary
Methods for modulating lipoprotein lipase (LPL) and Apoliprotein C2 (ApoC2) expression and/or activity in the treatment of peripheral and central nervous system tissue disease states with C-6 substituted estradiol derivatives are presented herein.